Comment Summary

In November 2007 the FDA changed the labeling on ESAs after several studies showed that certain dosages of some of these drugs were associated with more rapid growth of certain cancers and reduced survival rates. Do you agree with the conclusions of these studies?
#	Response Date	Other (please specify)
1.	3/3/2008 7:36:00 PM	not sure, more well designed studies are needed
2.	3/4/2008 9:34:00 AM	cannot answer